Coherus to repurchase $170M of convertible notes, conditional on UDENYCA sale close

Coherus Oncology, Inc.

Coherus agreed to repurchase ~$170M aggregate principal of its 1.500% Convertible Notes due 2026 at 100% par plus accrued interest.
Repurchases conditioned on closing of UDENYCA franchise divestiture to Intas Pharmaceuticals, expected early Q2 2025.
After repurchase, ~$60M of notes remain; Coherus plans a repurchase offer for those notes post-close.
Holders representing a majority of outstanding notes consented to indenture amendments permitting the UDENYCA divestiture.
Amendments executed via supplemental indenture dated March 31, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.